OncLive TV

Yubin Kang, MD, a professor of medicine and member of Duke Cancer Institute, discusses the preclinical activity of the SK-2 inhibitor ABC294640 in multiple myeloma.

Viola W. Zhu, MD, PhD, medical oncologist/hematologist, University of California, Irvine, discusses tumor mutational burden (TMB) in lung cancer.

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses advances made in the adjuvant setting of renal cell carcinoma (RCC).

Philip A. Philip, MD, PhD, FRCP, professor, Department of Oncology, Karmanos Cancer Institute, discusses the impact of the PRODIGE 24/CCTG PA.6 study in pancreatic cancer.

Bassel El-Rayes, MD, chief clinical research scientist, Winship Cancer Institute of Emory University, discusses methods of locoregional therapy in metastatic colorectal cancer.

Guru P. Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses the potential for neoadjuvant immunotherapy in bladder cancer.

Sai-Hong I. Ou, MD, PhD, professor, Division of Hematology/Oncology, Department of Medicine, University of California Irvine School of Medicine, discusses investigational KRAS inhibitors in lung cancer.

Richard (Rick) JaeBong Lee, MD, PhD, medical oncologist at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School, discusses results from the phase III ARAMIS trial in nonmetastatic castration-resistant prostate cancer (M0CRPC).

Vaibhav Sahai, MBBS, assistant professor of medicine at the University of Michigan, discusses the role of genomic profiling in pancreatic cancer.

Sarah Ferguson, MD, FRCSC, associate professor of gynecologic oncology, University of Toronto, Princess Margaret Cancer Centre, discusses adverse events associated with surgery in cervical cancer.

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the correlation between tumor sidedness and biomarkers in colorectal cancer.

Matthew S. McKinney, MD, assistant professor of medicine, Duke University School of Medicine, co-director of the Molecular Tumor Board, Duke Cancer Institute, discusses ongoing work in mantle cell lymphoma.

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the promise of single-agent pembrolizumab in advanced non–clear cell renal cell carcinoma.

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses drawbacks of radiation therapy in prostate cancer.

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the use of immunotherapy in oligometastatic non–small cell lung cancer.

Wells A. Messersmith, MD, co-director of the Developmental Therapeutics Program, and director, GI Cancer Program, at the University of Colorado School of Medicine, discusses molecular markers to be aware of in patients with colorectal cancer (CRC).

Cristina Gasparetto, MD, an associate professor of medicine and director, Multiple Myeloma Program at Duke Cancer Institute, discusses therapies for patients with penta-refractory multiple myeloma.

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses therapeutic agents under investigation for patients with PD-L1–low bladder cancer.

Yee Chung Cheng, MD, associate professor of medicine, Medical College of Wisconsin, discusses the role of T-DM1 in patients with HER2-positive breast cancer.

Timothy Fenske, MD, MS, an associate professor at the Medical College of Wisconsin, discusses targets under evaluation in mantle cell lymphoma.

Neal E. Ready, MD, PhD, professor of medicine, Duke University School of Medicine, member, Duke Cancer Institute, discusses the benefit of PD-L1 inhibition in small cell lung cancer.

Sameem Abedin, MD, assistant professor, Medical College of Wisconsin, discusses the role of venetoclax plus obinutuzumab in chronic lymphocytic leukemia.

Richard T. Maziarz, MD, professor of medicine at Oregon Health & Science University, Knight Cancer Institute, discusses unanswered questions with CAR T-cell therapy in diffuse large B-cell lymphoma.

Brian M. Shuch, MD, director, Kidney Cancer Program, Alvin & Carrie Meinhardt Endowed Chair of Kidney Cancer Research, University of California, Los Angeles Institute of Urologic Oncology, discusses caveats of the avelumab plus axitinib combination in frontline advanced renal cell carcinoma.

Thomas E. Stinchcombe, MD, professor of medicine, Duke Cancer Institute, discusses the benefit of alectinib in the treatment of patients with ALK-positive non–small cell lung cancer.

Rozita Yarmand, PhD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders-Research, The University of Texas MD Anderson Cancer Center, discusses unmet needs in medullary thyroid cancer.

John Sweetenham, MD, associate director for clinical affairs, Harold G. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, discusses unanswered questions with CAR T-cell therapy in pediatric acute lymphoblastic leukemia.

Peter Schmid, MD, PhD, lead at the Centre for Experimental Cancer Medicine, Barts Cancer Institute, discusses challenges with biosimilars in oncology.

Lyndsey Runaas, MD, an assistant professor at the Medical College of Wisconsin, discusses impactful targeted therapies for patients with FLT3-mutant acute myeloid leukemia (AML).

David A. Reardon, MD, clinical director, Center for Neuro-Oncology, institute physician, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses the immunogenicity of glioblastoma.